CORD-19:013ce450f63ae2496b92f987e35b55125a43947f / 12282-12355 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/013ce450f63ae2496b92f987e35b55125a43947f","sourcedb":"CORD-19","sourceid":"013ce450f63ae2496b92f987e35b55125a43947f","text":"Is PRCV a more effective candidate vaccine for TGEV than attenuated TGEV?","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T56","span":{"begin":0,"end":73},"obj":"Sentence"},{"id":"TextSentencer_T56","span":{"begin":0,"end":73},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T56","pred":"source","obj":"CORD-19-Sentences"},{"subj":"TextSentencer_T56","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T56","span":{"begin":0,"end":73},"obj":"Sentence"}],"attributes":[{"subj":"T56","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ec93d0","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93eaec"}]}]}}